Associate Clinical Professor
Pediatrics and Neurosurgery
Los Angeles Biomedical Research Institute
United States of America
Cancer afflicts 12,000 children per year in the United States. Although current therapies can cure over 80% of these children, many are left with devastating long term side effects. Dr. Lasky's research team is interested in using genomic, epigenetic, metabolomic, and immunologic approaches in a clinical, translational, and basic science to target childhood cancers more effectively and in a less toxic fashion. Specifically, Dr. Lasky's team has studied sensitized T-lymphocytes in animal models as an adoptive immunotherapy in combination with chemotherapy as well as metabolic inhibitors in combination with other therapies to slow or stop tumor growth. In addition to oncology, Dr. Lasky also participate in clinical and translational work in sickle cell disease (SCD). Over 100,000 people in the United States suffer from sickle cell disease and its complications (such as pain, kidney failure, and decreased life span). He is working with other researchers at LA BioMed to discover novel therapies to ameliorate the complications of this disease.
Genomic, epigenetic, metabolomic, and immunologic approaches in a clinical, translational, and basic science to target childhood cancers more effectively and in a less toxic fashion
Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. Journal of Neuro-Oncology. 2013
Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent High-grade Gliomas. Anticancer Research.
Cancer Stem Cells in Brain Tumors. Curr Signal Transduct Ther;